FEN1 promotes cancer progression of cholangiocarcinoma by regulating the Wnt/β-catenin signaling pathway.

[1]  Zhigang Guo,et al.  Small-Molecule Inhibitors Targeting FEN1 for Cancer Therapy , 2022, Biomolecules.

[2]  Yan Zhou,et al.  Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway , 2022, BMB reports.

[3]  C. Braconi,et al.  Metabolic Reprogramming in Cholangiocarcinoma. , 2022, Journal of hepatology.

[4]  Yingjian Wang,et al.  miR-4324 inhibits ovarian cancer progression by targeting FEN1 , 2022, Journal of Ovarian Research.

[5]  Chengzhan Zhu,et al.  Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma , 2021, Cellular Oncology.

[6]  T. Tot,et al.  Integrative meta-analysis of gene expression profiles identifies FEN1 and ENDOU as potential diagnostic biomarkers for cervical squamous cell carcinoma , 2021, Oncology letters.

[7]  Fuan Wang,et al.  Precision Spherical Nucleic Acids Enable Sensitive FEN1 Imaging and Controllable Drug Delivery for Cancer-Specific Therapy. , 2021, Analytical chemistry.

[8]  P. Zhou,et al.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[9]  Penghui Wang,et al.  Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer , 2021, Frontiers in Oncology.

[10]  David M. Wilson,et al.  FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers , 2021, Cancers.

[11]  Wei Wei,et al.  Fluorescent Assay of FEN1 Activity with Nicking Enzyme-Assisted Signal Amplification Based on ZIF-8 for Imaging in Living Cells. , 2021, Analytical chemistry.

[12]  X. Che,et al.  FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis , 2021, Annals of translational medicine.

[13]  Lingfeng He,et al.  PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells. , 2020, DNA repair.

[14]  R. Kolodner,et al.  FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination , 2020, Proceedings of the National Academy of Sciences.

[15]  C. Mussolino,et al.  DNA Damage: From Threat to Treatment , 2020, Cells.

[16]  G. Gores,et al.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management , 2020, Nature Reviews Gastroenterology & Hepatology.

[17]  E. Zhao,et al.  Flap endonuclease 1 (FEN1) as a novel diagnostic and prognostic biomarker for gastric cancer. , 2020, Clinics and research in hepatology and gastroenterology.

[18]  Zujiang Yu,et al.  Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma , 2020, Disease markers.

[19]  Zhigang Guo,et al.  FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells , 2019, Cancer medicine.

[20]  Y. Teng,et al.  FEN1 mediates miR‐200a methylation and promotes breast cancer cell growth via MET and EGFR signaling , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Lingfeng He,et al.  MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer , 2019, Oncogene.

[22]  P. Hu,et al.  TGFβ1- miR-140-5p axis mediated up-regulation of Flap Endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma , 2019, Aging.

[23]  H. Ansari,et al.  Association between the flap endonuclease 1 gene polymorphisms and cancer susceptibility: An updated meta‐analysis , 2019, Journal of cellular biochemistry.

[24]  J. Marin,et al.  Wnt–β-catenin signalling in liver development, health and disease , 2018, Nature Reviews Gastroenterology & Hepatology.

[25]  Kuen-Feng Chen,et al.  Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. , 2018, European journal of cancer.

[26]  Hong Zhu,et al.  Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells. , 2018, DNA repair.

[27]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[28]  Michael S. Goldberg,et al.  DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.

[29]  Ziheng Zhuang,et al.  FEN1 promotes tumor progression and confers cisplatin resistance in non‐small‐cell lung cancer , 2017, Molecular oncology.

[30]  T. Bekaii-Saab,et al.  Next‐generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance , 2016, Cancer.

[31]  E. Swisher,et al.  Biomarkers of Response and Resistance to DNA Repair Targeted Therapies , 2016, Clinical Cancer Research.

[32]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[33]  Hiromi Nakamura,et al.  Genomic spectra of biliary tract cancer , 2015, Nature Genetics.

[34]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[35]  L. Finger,et al.  Functional regulation of FEN1 nuclease and its link to cancer , 2010, Nucleic acids research.

[36]  G. Gores,et al.  Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. , 2000, Cancer research.